Buprenorphine - A review of its role in neuropathic pain

Journal of Opioid Management

Volumn 3, Issue 4, 2007, Pages 195-206

  Hans, Guy ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Allodynia; Buprenorphine; Hyperalgesia; Neuropathic pain; Opioids; Sensitization

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; DIHYDROCODEINE; FENTANYL; FENTANYL CITRATE; FLUNIXIN; FORMALDEHYDE; KAPPA OPIATE RECEPTOR; LEVOPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; OPIATE DERIVATIVE; PERTUSSIS TOXIN; PLACEBO; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIA; ANTINOCICEPTION; CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTACT DERMATITIS; CONVULSION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVIDENCE BASED MEDICINE; FATIGUE; HALLUCINATION; HUMAN; HYPERALGESIA; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; MICTURITION DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; OPTIMAL DRUG DOSE; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRURITUS; RESPIRATION DEPRESSION; RESPIRATORY ARREST; REVIEW; SENSITIVITY ANALYSIS; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; VERTIGO; VOMITING;

EID: 35348941744     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2007.0005     Document Type: Review

References (93)

1. Colombo B, Annovazzi PO, Comi G: Medications for neuropathic pain: Current trends. Neurol Sci. 2006; 27 (Suppl 2): S183-S189.
2. McCleane G: Pharmacological strategies in relieving neuropathic pain. Expert Opin Pharmacother. 2004; 5(6): 1299-1312.
3. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain. 1999; 83(3): 389-400.
4. Rasmussen PV, Sindrup SH, Jensen TS, et al.: Therapeutic outcome in neuropathic pain: Relationship to evidence of nervous system lesion. Eur J Neurol. 2004; 11(8): 545-553.
5. Finnerup NB, Otto M, McQuay HJ, et al.: Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118(3): 289-305.
6. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988; 33: 11-23.
7. Raja S, Haythonwaite J, Pappagallo M: Opioids versus antidepressants in postherpetic neuralgia: A randomised, placebo controlled trial. Neurology. 2002; 59: 1015-1021.
8. Rowbotham MC: The debate over opioids and neuropathic pain. In Kalso E, McQuay HJ, Wiesenfeld-Hallin Z (eds.): Opioid Sensitivity of Noncancer Pain - Progress in Pain Research and Management. vol. 14. Seattle: IASP Press, 1999: 307-317.
9. Guirguis-Blake J, Kelly C: Are opioids effective in the treatment of neuropathic pain? Am Fam Physician. 2007; 75(7): 999-1001.
10. Rowbotham MC, Twilling L, Davies PS, et al.: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003; 348(13): 1223-1232.
11. Eisenberg E, McNicol E, Carr DB: Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006; 19(3): CD006146.
12. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al.: Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006; 174(11): 1589-1594.
13. Budd K: Buprenorphine: A Review. Evidence Based Medicine in Practice. Newmarket: Hayward Medical Communications, 2002.
14. Cowan A, Friderichs F, Straßurger W, et al.: Basic pharmacology of buprenorphine. In Budd K, Raffa RB (eds.): Buprenorphine - The Unique Opioid Analgesic. Pharmacology and Clinical Application. Stuttgart: George Thieme Verlag KG, 2005: 3-21.
15. Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain. 1990; 43(3): 273-286.
16. Wall PD: Neuropathic pain. Pain. 1990; 43(3): 267-268.
17. Dellemijn P: Are opioids effective in relieving neuropathic pain? Pain. 1999; 80(3): 453-462.
18. Jackson KC II. Pharmacotherapy for neuropathic pain. Pain Pract. 2006; 6(1): 27-33.
19. Jadad AR, Carroll D, Glynn CJ, et al.: Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. Lancet. 1992; 339(8806): 1367-1371.
20. Davis MP: What is new in neuropathic pain? Support Care Cancer. 2007; 15(4): 363-372.
21. Eisenberg F, McNicol E, Carr DB: Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006; 3: CD006146.
22. Watson CP, Watt-Watson JH, Chipman ML: Chronic noncancer pain and the long term utility of opioids. Pain Res Manag. 2004 Spring; 9(1): 19-24.
23. Gagnon B, Almahrezi A, Schreier G: Methadone in the treatment of neuropathic pain. Pain Res Manag. 2003 Fall; 8(3): 149-154.
24. Morley JS, Bridson J, Nash TP, et al.: Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med. 2003; 17(7): 576-587.
25. Moulin DE, Palma D, Watling C, et al.: Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci. 2005; 32(3): 340-343.
26. Watson CP, Moulin D, Watt-Watson J, et al.: Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105(1/2): 71-78.
27. Eisenberg E, McNicol ED, Carr DB: Efficacy of μ-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain. 2006; 10: 667-676.
28. Cowan A, Lewis JW, Macfarlane IR: Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977; 60(4): 537-545.
29. McCormack K, Prather P, Chapleo C: Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain. 1998; 78(2): 79-98.
30. Pick CG, Peter Y, Schreiber S, et al.: Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with κ3 analgesia. Brain Res. 1997; 744(1): 41-46.
31. Schreiber S, Backer MM, Yanai J, et al.: The antinociceptive effect of fluvoxamine. Eur Neuropsychopharmacol. 1996; 6(4): 281-284.
32. McLaughlin CR, Tao Q, Abood ME: Analysis of the antinociceptive actions of the κ-opioid agonist enadoline (CI-977) in neonatal and adult rats: Comparison to κ-opioid receptor mRNA ontogeny. Drug Alcohol Depend. 1995; 38(3): 261-269.
33. Sanchez JA, Gonoi T, Inagaki N, et al.: Modulation of reconstituted ATP-sensitive K(+)-channels by GTP-binding proteins in a mammalian cell line. J Physiol. 1998; 507 (Part 2): 315-324.
34. Wada Y, Yamashita T, Imai K, et al.: A region of the sulfonylurea receptor critical for a modulation of ATP-sensitive K(+) channels by G-protein βγ-subunits. EMBO J. 2000; 19(18): 4915-4925.
35. Mark MD, Herlitze S: G-protein mediated gating of inward-rectifier K+ channels. Eur J Biochem. 2000; 267(19): 5830-5836.
36. Ocana M, Del Pozo F, Barrios M, et al.: Subgroups among μ-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs. Br J Pharmacol. 1995; 114(6): 1296-1302.
37. Wood JN, Abrahamsen B, Baker MD, et al.: Ion channel activities implicated in pathological pain. Novartis Found Symp. 2004; 261: 32-40; Discussion 40-54.
38. Yang EK, Takimoto K, Hayashi Y, et al.: Altered expression of potassium channel subunit mRNA and α-dendrotoxin sensitivity of potassium currents in rat dorsal root ganglion neurons after axotomy. Neuroscience. 2004; 123(4): 867-874.
39. Bloms-Funke P, Gillen C, Schuettler AJ, et al.: Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides. 2000; 21(7): 1141-1146.
40. Hawkinson JE, Acosta-Burruel M, Espitia SA: Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol. 2000; 389(2/3): 107-114.
41. Huang P, Kehner GB, Cowan A, et al.: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001; 297(2): 688-695.
42. Wnendt S, Kruger T, Janocha E, et al.: Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol. 1999; 56(2): 334-338.
43. Lutfy K, Eitan S, Bryant CD, et al.: Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003; 23(32): 10331-10337.
44. Hentz JG, Valle-Robillart A, Franckhauser J, et al.: The use of intrathecal morphine in thoracic anesthesia. J Cardiothorac Anesth. 1989; 3 (5 Suppl 1): 24.
45. Lundborg CN, Nitescu PV, Appelgren LK, et al.: Progressive systemic sclerosis: Intrathecal pain management. Reg Anesth Pain Med. 1999 Jan-Feb; 24(1): 89-93.
46. Nitescu P, Dahm P, Appelgren L, et al.: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain. Clin J Pain. 1998; 14(1): 17-28.
47. Tejwani GA, Rattan AK: The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg. 2002; 94(6): 1542-1546.
48. Guirimand F, Chauvin M, Willer JC, et al.: Effects of intrathecal and intracerebroventricular buprenorphine on a C-fiber reflex in the rat. J Pharmacol Exp Ther. 1995; 275(2): 629-637.
49. Inagaki Y, Mashimo T, Yoshiya I: Mode and site of analgesic action of epidural buprenorphine in humans. Anesth Analg. 1996; 83(3): 530-536.
50. McLaughlin CR, Dewey WL: A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol Biochem Behav. 1994; 49(4): 1017-1023.
51. Guirimand F, Chauvin M, Willer JC, et al.: Buprenorphine blocks diffuse noxious inhibitory controls in the rat. Eur J Pharmacol. 1995; 294(2/3): 651-659.
52. Kakigi R: Diffuse noxious inhibitory control. Reappraisal by pain-related somatosensory evoked potentials following CO2 laser stimulation. J Neurol Sci. 1994; 125(2): 198-205.
53. Le Bars D, Chitour D, Kraus E, et al.: The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: Evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res. 1981; 215(1/2): 257-274.
54. Ciruela A, Dixon AK, Bramwell S, et al.: Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003; 138: 751-756.
55. Jin SX, Zhuang ZY, Woolf CJ, et al.: p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003; 23(10): 4017-4022.
56. Milligan ED, Twining C, Chacur M, et al.: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003; 23(3): 1026-1040.
57. Womer DE, DeLapp NW, Shannon HE: Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain. 1997; 70(2/3): 223-228.
58. Wheeler-Aceto H, Cowan A: Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol. 1991; 195(3): 411-413.
59. Wang JJ, Ho ST, Hu OY, et al.: An innovative cold tail-flick test: The cold ethanol tail-flick test. Anesth Analg. 1995; 80(1): 102-107.
60. Kouya PF, Hao JX, Xu XJ: Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol. 2002; 450(1): 49-53.
61. Xu XJ, Hao JX, Aldskogius H, et al.: Chronic pain-related syndrome in rats after ischemic spinal cord lesion: A possible animal model for pain in patients with spinal cord injury. Pain. 1992; 48(2): 279-290.
62. Yu W, Hao JX, Xu XJ, et al.: Comparison of the anti-allodynic and antinociceptive effects of systemic; intrathecal and intracerebroventricular morphine in a rat model of central neuropathic pain. Eur J Pain. 1997; 1(1): 17-29.
63. Kupers R, Yu W, Persson JK, et al.: Photochemically-induced ischemia of the rat sciatic nerve produces a dose-dependent and highly reproducible mechanical, heat and cold allodynia, and signs of spontaneous pain. Pain. 1998; 76(1/2): 45-59.
64. Bulka A, Plesan A, Xu XJ, et al.: Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain. 2002; 95: 103-109.
65. Stewart LS, Martin WJ: Influence of postoperative analgesics on the development of neuropathic pain in rats. Comp Med. 2003; 53(1): 29-36.
66. Christoph T, Kogel B, Schiene K, et al.: Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol. 2005; 507: 87-98.
67. Koppert W, Ihmsen H, Korber N, et al.: Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005; 118(1/2): 15-22.
68. Sittl R: Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005; 5(3): 315-323.
69. Staats P, Johnson R: New perspectives on the pharmacology of opioids and their use in chronic pain. Prog Anaesthesiol. 2002; 16: 235-249.
70. Likar R: Transdermal buprenorphine in the management of persistent pain - Safety aspects. Ther Clin Risk Manag. 2006 2(1): 115-125.
71. Walsh SL, Preston KL, Stitzer ML, et al.: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994; 55(5): 569-580.
72. Böhme K: Buprenorphine in a transdermal therapeutic system - A new option. Clin Rheumatol. 2002; 21 (Suppl 1): S13-S16.
73. Johnson RE, Fudala PJ, Payne R: Buprenorphine: Considerations for pain management. J Pain Symptom Manage. 2005; 29(3): 297-326.
74. Dahan A: Opioid-induced respiratory effects: New data on buprenorphine. Palliat Med. 2006; 20 (Suppl 1): s3-s8.
75. Zenz M, Strumpf M, Tryba M: Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage. 1992; 7(2): 69-77.
76. Omote K, Ohmori H, Kawamata M, et al.: Intrathecal buprenorphine in the treatment of phantom limb pain. Anesth Analg. 1995; 80(5): 1030-1032.
77. Gotoda Y, Kambara N, Sakai T, et al.: The morbidity, time course and predictive factors for persistent post-thoracotomy pain. Eur J Pain. 2001; 5(1): 89-96.
78. Benedetti F, Vighetti S, Amanzio M, et al.: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain. 1998; 74: 205-211.
79. Kalia YN, Merino V, Guy RH: Transdermal drug delivery. Clinical aspects. Dermatol Clin. 1998; 16(2): 289-299.
80. Sittl R, Griessinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003; 25(1): 150-168.
81. Sorge J, Sittl R: Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004; 26(11): 1808-1820.
82. Likar R, Kayser H, Sittl R: Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006; 28(6): 943-952.
83. Rodriguez-Lopez M: Transdermal buprenorphine in the treatment of neuropathic pain. Rev Soc Esp Dolor. 2004; 11: S11-S21.
84. Likar R, Sittl R: Transdermal buprenorphine for treating nociceptive and neuropathic pain: Four case studies. Anesth Analg. 2005; 100(3): 781-785.
85. Louis F: Transdermal buprenorphine in pain management - Experiences from clinical practice: Five case studies. Int J Clin Pract. 2006; 60(10): 1330-1334.
86. Griessinger N, Sittl R, Likar R: Transdermal buprenorphine in clinical practice - A post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005; 21(8): 1147-1156.
87. Radbruch L, Sabatowski R, Petzke F, et al.: Transdermal fentanyl for the management of cancer pain: A survey of 1005 patients. Palliat Med. 2001; 15(4): 309-321.
88. Sittl R, Likar R, Nautrup BP: Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther. 2005; 27(2): 225-237.
89. Sittl R, Nuijten M, Nautrup BP: Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany. Clin Ther. 2006; 28(8): 1144-1154.
90. Dertwinkel R, Donner B, Zenz M, Schulz S, Bading B: Opioids in chronic pain. Baillère's Clin Anaesthesiol. 1998; 12(1): 39-52.
91. Doxey J, Everitt J, Frank L, et al.: A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. Brit J Pharmacol. 1982; 75: 118P.
92. Dahan A, Yassen A, Bijl H, et al.: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005; 94(6): 825-834.
93. van Dorp E, Yassen A, Sarton E, et al.: Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006; 105(1): 51-57.